頭孢菌素市場規模、佔有率、趨勢和預測：按代、給藥途徑、應用和地區分類（2026-2034 年）

2025年全球頭孢菌素市場規模為202億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以2.35%的複合年成長率成長，到2034年達到251億美元。目前，亞太地區是該市場的主要驅動力，預計2025年將佔據40.5%的市場。該市場正經歷穩定成長，這主要得益於抗生素抗藥性感染疾病的日益普遍、對有效且安全治療方法的需求，以及為推出新型頭孢菌素製劑而持續開展的研發活動。此外，醫院對先進注射劑型的依賴以及穩定的治療效果，也持續支撐著頭孢菌素在重症監護和門診領域的市場佔有率。

頭孢菌素市場正經歷強勁成長，這主要得益於市場對頻譜抗生素的旺盛需求。這些抗生素廣泛用於治療各種細菌感染疾病，包括對傳統治療方法抗藥性的感染。頭孢菌素因其對多種疾病有效而備受醫生青睞，因為它們能夠抑制革蘭氏陽性菌和革蘭氏陰性菌。呼吸道感染疾病、皮膚感染疾病和醫院感染病例的不斷增加持續推動著這項需求。人口密度高且初級醫療保健服務有限的國家，例如印度、印尼和奈及利亞，對此成長趨勢的貢獻尤其顯著。此外，醫療專業人員也積極轉向使用能夠改善臨床療效並減少副作用的新型頭孢菌素。

注射用頭孢菌素在美國的使用日益增多，因為它們在治療嚴重感染疾病療效顯著，且符合醫院的醫療標準。它們被廣泛應用於急診、住院病房和外科等需要即時反應的科室。由於起效迅速且生物利用度高，美國醫護人員通常選擇注射劑型治療肺炎、敗血症和複雜性尿道感染。抗生素抗藥性的日益嚴重也推動了市場需求，醫院正轉向療效確切、可靠的治療方法。 2023年底至2024年間，多家美國製藥公司拓展了其注射用抗生素產品線，重點研發能夠減少給藥頻率並提高安全性的頭孢菌素製劑。醫院採購部門也越來越傾向於選擇這些新藥，因為他們希望最佳化治療方案並縮短住院時間。

頭孢菌素市場趨勢：

細菌感染疾病呈上升趨勢

全球細菌感染疾病的增加推動了頭孢菌素的需求，而頭孢菌素的需求是市場的主要促進因素。這些抗生素對於治療肺炎、鼻竇炎、扁桃腺炎、葡萄球菌感染疾病和鏈球菌咽頭炎等常見和嚴重至關重要。 2019年的報告指出，全球有超過700萬人死於細菌感染疾病，凸顯了對可靠治療方法的持續需求。由於頭孢菌素具有頻譜抗菌作用，適用於廣泛的患者群體，因此仍是首選治療方案。人口成長、某些地區衛生條件惡化以及許多地區早期治療機會有限，都加劇了感染疾病負擔。美國疾病管制與預防中心（CDC）和世界衛生組織（WHO）等衛生機構持續報告細菌性疾病發生率激增，並敦促廣泛使用已建立的抗生素。社會對早期療育和衛生教育的日益重視，有助於提高診斷率，進而增加對抗生素的需求。感染疾病的增加，尤其是在開發中國家，意味著頭孢菌素類藥物將繼續在醫院和基層醫療機構廣泛使用。由於其安全性高且對多種細菌菌株有效，頭孢菌素類藥物仍是全球最值得信賴的抗生素之一。

產品變體方面的進展

近年來，製藥技術的進步推動了頭孢菌素製劑的改良，使其對抗藥性菌株的療效更佳。這些新型製劑對革蘭氏陰性菌具有更強的抗菌活性，而革蘭氏陰性菌由於其具有保護性外層，治療難度較高。藥物化學領域的創新也促成了更有效的第三代和第四代頭孢菌素的研發，用於治療複雜感染疾病。根據美國國立衛生研究院 (NIH) 統計，細菌抗藥性仍然是全球面臨的嚴重威脅，2021 年造成超過一百萬人死亡。為了應對這項挑戰，製藥公司正致力於開發更具針對性的解決方案。他們加大研發投入，開發能應付這些新挑戰的新一代頭孢菌素。這些努力包括提高吸收率、減少給藥頻率、以及最大限度地降低副作用。一些新推出的產品也提高了藥物對感染部位的滲透性，從而產生更快、更持久的療效。這些進步使得現代頭孢菌素能夠有效治療難治性感染疾病和院內感染。對有效治療方法日益成長的需求預計將推動該領域的發展。在全球企業加大投資的支持下，持續的研發將促使更多先進產品推向市場，這有望維持頭孢菌素類藥物全球市場的成長。

公眾意識的提高和政府舉措

公共衛生機構和政府為促進合理使用抗生素所做的努力正在推動頭孢菌素市場的發展。隨著人們對抗生素濫用和抗藥性風險的認知不斷提高，健康宣傳宣傳活動鼓勵及時、適當地治療細菌感染疾病。這些計畫旨在教育大眾如何安全有效地使用包括頭孢菌素在內的抗生素。除了這些宣傳活動外，許多國家還在增加醫療保健支出，以改善基本藥物的可近性。印度就是一個典型的例子，其政府在2024年初宣布了200多個醫療保健基礎設施項目，總投資額約為117億印度盧比。這些措施旨在改善服務不足地區的醫療保健服務，這必然會增加對基本抗生素的需求。隨著健康意識的提高和醫療保健基礎設施的改善，越來越多的患者能夠獲得準確的診斷和適當的治療。這使得抗生素的使用在更廣泛的人群中更加規範。政府的支持也促進了治療方案的標準化，這些方案建議使用頭孢菌素等頻譜抗生素，而這些抗生素在治療各種感染疾病仍然至關重要。隨著越來越多的國家努力加強醫療保健系統並教育患者，頭孢菌素市場預計將穩定成長。

醫療基礎建設

醫療基礎設施的改善，尤其是在中低收入國家，正在擴大抗生素的可近性，並改善細菌感染疾病的治療。設備齊全的醫院、診所和診斷中心使醫護人員能夠更方便地使用頭孢菌素類藥物診斷和治療感染疾病。診斷手段的普及和患者追蹤系統的改進也有助於更早發現感染疾病並進行更及時的治療。截至2023年3月，印度全國擁有約32,000個基層醫療中心和700多家地區醫院，都市區地區的覆蓋範圍都在擴大。隨著更多醫療機構具備開立具有效藥物的能力，這種擴張直接影響抗生素的使用率。隨著現代治療在農村地區變得更加普及，對可靠且價格合理的抗生素的需求持續成長。頭孢菌素類藥物以其廣譜療效和安全性而聞名，在許多地區仍然是首選治療藥物。對醫療基礎設施的持續投資將繼續支持頭孢菌素市場的成長，尤其是在感染控制措施執行更嚴格的地區。隨著醫療保健系統的成熟，對高效且廣泛接受的抗生素的需求預計將會增加，這將進一步鞏固頭孢菌素在常規臨床實踐中的地位。

目錄

第1章：序言

第2章：調查方法

• 調查目的
• 相關利益者
• 數據來源
  • 主要訊息
  • 二手資訊
• 市場估值
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第3章執行摘要

第4章：引言

第5章：全球頭孢菌素市場

• 市場概覽
• 市場表現
• 新冠疫情的影響
• 市場區隔：按世代分類
• 市場區隔：依給藥途徑
• 市場區隔：按應用領域
• 市場區隔：按地區
• 市場預測

第6章 市場區隔：依世代分類

• 第一代
• 第二代
• 第三代
• 第四代
• 第五代

第7章 市場區隔：依給藥途徑

• 注射
• 口服

第8章 市場區隔：依應用領域分類

• 呼吸系統
• 皮膚感染疾病
• 耳部感染疾病
• 尿道感染
• 性行為感染傳染病
• 其他

第9章 市場區隔：依地區分類

• 亞太地區
• 歐洲
• 北美洲
• 中東和非洲
• 拉丁美洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

• 價格指標
• 價格結構
• 利潤分析

第14章 競爭格局

• 市場結構
• 大公司
• 主要公司簡介
  • Allergan Plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Lupin Limited
  • Merck & Co. Inc.
  • Novartis International AG（Sandoz）
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Abbott
  • Sun Pharmaceutical Industries Limited

The global cephalosporin market size was valued at USD 20.2 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 25.1 Billion by 2034, exhibiting a CAGR of 2.35% during 2026-2034. Asia-Pacific currently dominates the market, holding a significant market share of 40.5% in 2025. The market is experiencing steady growth driven by increasing antibiotic-resistant infections, the demand for effective and safer treatment options, ongoing research and development efforts to introduce new cephalosporin formulations. In addition, hospital reliance on advanced injectables and consistent treatment outcomes continues to support cephalosporin market share across critical care and outpatient settings.

The market for cephalosporins is experiencing robust growth due to high demand for broad-spectrum antibiotics. These antibiotics are widely used in the treatment of various bacterial infections, including those resistant to traditional treatments. Doctors favor cephalosporins because they inhibit both Gram-positive and Gram-negative bacteria, making them effective against a broad spectrum of ailments. The increasing number of cases of respiratory tract infections, skin infections, and hospital-acquired infections continues to drive this demand. Population-dense countries with limited access to early care, such as India, Indonesia, and Nigeria, are significantly contributing to this growing trend. Healthcare professionals are also turning to newer cephalosporins, which offer improved clinical outcomes and fewer side effects.

Injectable cephalosporins are increasingly being utilized in the United States because they are highly effective for treating serious infections and also meet hospital standards for care. They are widely used in emergency rooms, inpatient units, and surgical units where immediate action is required. US healthcare professionals often opt for injectable formulations in cases of pneumonia, sepsis, and complex urinary tract infections because they have a quicker onset and greater bioavailability. Demand is also fueled by increasing incidences of antimicrobial resistance, making hospitals switch to trusted treatments with established clinical effectiveness. Throughout late 2023 and into 2024, several US-based drug manufacturers diversified their injectable antibiotic product lines, focusing on cephalosporin preparations that reduce the frequency of dosing and enhance safety. Hospital purchasing departments have increasingly favored these newer agents as they seek to maximize treatment protocols and minimize hospital stays.

CEPHALOSPORIN MARKET TRENDS:

Increasing Prevalence of Bacterial Infections

Rising global cases of bacterial infections are driving demand for cephalosporins, a significant factor in the market. These antibiotics are essential for treating common and severe conditions such as pneumonia, sinus infections, tonsillitis, staph infections, and strep throat. Reports from 2019 indicated over 7 Million deaths were linked to bacterial infections globally, demonstrating the continued need for dependable treatment options. Cephalosporins remain a top choice due to their broad-spectrum capabilities and suitability for different patient groups. Population growth, poor sanitation in certain areas, and limited access to early treatment in many regions contribute to the increasing burden of infection. Health authorities, such as the CDC and WHO, continue to report sharp increases in bacterial disease rates, prompting the widespread use of established antibiotic classes. Public interest in early intervention and hygiene education is helping drive up diagnosis rates, which in turn boosts the demand for antibiotics. The growing number of infections, particularly in developing countries, means that cephalosporins will continue to be widely used in both hospitals and primary care settings. Their safety profile and effectiveness against a wide range of bacterial strains keep them among the most trusted antibiotics globally.

Advancements in Product Variants

Recent pharmaceutical advancements have led to the development of improved cephalosporin formulations that are more effective against resistant bacterial strains. These newer versions offer enhanced action against Gram-negative bacteria, which are harder to treat due to their protective outer layers. Innovations in drug chemistry have led to the development of third- and fourth-generation cephalosporins, which are more effective in managing complex infections. Bacterial resistance remains a serious global threat, contributing to over a Million deaths in 2021, according to the National Institutes of Health. This has prompted drug developers to create more targeted solutions. Pharmaceutical companies are increasing research investments to produce next-generation cephalosporins that address these emerging challenges. These efforts include improving absorption rates, reducing the frequency of dosing, and minimizing side effects. Some recent products have also demonstrated improved penetration into infection sites, providing quicker and more sustained effects. These developments have made modern cephalosporins suitable for treating infections that are difficult to treat and hospital-acquired conditions. The growing demand for effective treatment options is expected to sustain development in this segment. Continued R&D, backed by growing investments from global firms, will likely bring more advanced products to the market, helping to sustain global cephalosporin market growth in the cephalosporin segment.

Growing Awareness and Government Initiatives

Efforts by public health agencies and governments to promote responsible antibiotic use are strengthening the cephalosporin market. As awareness grows about the dangers of antibiotic misuse and resistance, health campaigns are encouraging timely and proper treatment of bacterial infections. These programs focus on educating communities about how and when to use antibiotics, including cephalosporins, safely and effectively. Alongside public outreach, many countries are expanding their healthcare spending to improve access to essential medicines. One major example occurred in India, where the government announced over 200 health infrastructure projects in early 2024, totaling nearly INR 11,700 Crores. These developments are designed to improve health services in underserved regions, which will naturally raise the demand for critical antibiotics. With health awareness on the rise and medical infrastructure improving, more patients are receiving accurate diagnoses and appropriate treatments. This has led to more consistent use of antibiotics across a wide population. Government support also helps standardize treatment protocols that favor broad-spectrum antibiotics, such as cephalosporins, which remain vital in managing a wide variety of infections. As more countries commit to strengthening health systems and patient education, the market for cephalosporins is expected to see steady growth.

Developing Healthcare Infrastructure

Upgrades in healthcare infrastructure, particularly in low- and middle-income countries, are enhancing access to antibiotics and enhancing treatment for bacterial infections. Better-equipped hospitals, clinics, and diagnostic centers are making it easier for healthcare providers to diagnose and manage infections using cephalosporins. Expanded access to diagnostics and improved patient tracking systems also help identify infections earlier, leading to more timely treatments. As of March 2023, India had nearly 32,000 primary health centers and over 700 district hospitals nationwide, with expanding coverage in both urban and rural areas. This expansion plays a direct role in antibiotic usage rates, as more facilities are equipped to dispense effective drugs. As rural areas gain access to modern treatment, the demand for reliable and affordable antibiotics continues to climb. Cephalosporins, known for their broad effectiveness and safety profile, remain a first-line treatment in many of these settings. The ongoing investments in health infrastructure will continue to support cephalosporin market growth, especially where infection control programs are being implemented more rigorously. As healthcare systems mature, the need for efficient and widely accepted antibiotics is likely to increase, reinforcing the position of cephalosporins in daily clinical use.

CEPHALOSPORIN INDUSTRY SEGMENTATION:

Analysis by Generation:

• First Generation
• Second Generation
• Third Generation
• Fourth Generation
• Fifth Generation

As per the cephalosporin market outlook, in 2025, the third generation segment led the market, accounting for 38% of the total market share driven by its broad-spectrum activity against both Gram-positive and Gram-negative bacteria. These antibiotics are often prescribed for respiratory tract infections, meningitis, and gonorrhea, making them widely used in both hospital and outpatient settings. Their effectiveness against resistant strains further boosts demand. For instance, ceftriaxone remains a preferred choice in treating community-acquired pneumonia and severe infections due to its long half-life and ease of once-daily dosing, contributing to the dominance of third-generation cephalosporins in the global market.

Analysis by Route of Administration:

• Injection
• Oral

In 2025, the injection segment led the cephalosporin market, accounting for 67.7% of the total market share, driven by the need for rapid drug delivery in severe infections. Injectable cephalosporins are commonly used in hospitals to treat conditions such as sepsis, pneumonia, and post-surgical infections where oral antibiotics are ineffective. Their high bioavailability and immediate action make them essential in emergency and inpatient care. Drugs such as cefepime and ceftriaxone are routinely used via injection for managing critical infections, reinforcing the strong market demand for parenteral formulations and making the injection segment the most preferred route of administration in clinical settings.

Analysis by Application :

• Respiratory Tract
• Skin Infection
• Ear Infection
• Urinary Tract Infection
• Sexually Transmitted Infection
• Others

In 2025, the urinary tract infection led the cephalosporin market, accounting for 31.3% of the total market share, driven by the rising prevalence of urinary tract infections (UTIs) globally and the effectiveness of cephalosporins in treating both uncomplicated and recurrent cases of UTIs. These antibiotics provide reliable coverage against common uropathogens, such as E. coli. The increasing resistance to other antibiotic classes has made cephalosporins a go-to treatment. For example, cefixime is often prescribed for outpatient UTI management due to its safety and effectiveness. The high burden of UTIs, especially among women and the elderly, has kept demand for cephalosporins consistently strong in this therapeutic segment.

Regional Analysis:

• Asia Pacific
• Europe
• North America
• Middle East and Africa
• Latin America

In 2025, the Asia Pacific led the cephalosporin market, accounting for 40.5% of the total market share, driven by high rates of infectious diseases, increasing healthcare infrastructure, and the affordability of antibiotic production. Countries like India and China are major manufacturing hubs for generic cephalosporins, allowing for cost-effective supply across the region. Additionally, rising awareness, urban population growth, and supportive government healthcare initiatives are expanding access to antibiotics. For instance, India's large pharmaceutical base produces drugs like cefuroxime at scale, fulfilling both domestic and international demand. These factors collectively fuel Asia Pacific's leading position in the global cephalosporin market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES CEPHALOSPORIN MARKET ANALYSIS

In 2025, the United States accounted for 93.50 % of the cephalosporin market in North America, driven by multiple medical and economic factors. The widespread use of cephalosporins in treating infections, such as pneumonia, urinary tract conditions, and skin infections, has helped them become a standard option across various care settings. The rise in antimicrobial resistance is also leading to a stronger reliance on newer cephalosporin generations, particularly third- and fourth-generation drugs, which are more effective in addressing difficult bacterial strains. With approximately 2.8 Million antimicrobial-resistant infections occurring annually in the US, as reported by the CDC, the need for potent antibiotics remains a pressing concern. Major pharmaceutical firms based in the country are actively investing in research and development (R&D) to create more effective cephalosporin-based solutions tailored to specific bacterial threats. Additionally, precision medicine is influencing drug development, helping researchers build formulations that align more closely with patient and pathogen profiles. Regulatory support for affordable generic versions of these drugs has also improved access to them. The US market is witnessing an increase in the use of oral cephalosporins in outpatient settings, reflecting a shift toward home-based care. Altogether, ongoing innovation, government support, and rising infection rates are driving sustained demand for cephalosporins nationwide.

ASIA PACIFIC CEPHALOSPORIN MARKET ANALYSIS

The cephalosporin market in the Asia Pacific region is expanding due to rising healthcare investments, increasing infection rates, and growing awareness of the effectiveness of antibiotics. Countries like India and China are experiencing high demand, as their large populations and rising incidence of bacterial diseases fuel the need for dependable treatments. In India, healthcare spending increased from 1.4% in 2017-18 to 1.9% in 2023-24, growing at a rate of nearly 15.8% annually, according to government sources. This increase in funding is improving access to both hospital-based and outpatient treatments. Cephalosporins are widely used in this region because they are both effective and affordable, particularly in their generic form. Expanded healthcare access in rural and underserved communities is helping more patients receive proper treatment for common infections. The presence of domestic pharmaceutical manufacturers has also helped reduce costs and ensure a stable supply of pharmaceuticals. Both oral and injectable forms are seeing growing use, particularly in facilities that previously had limited antibiotic options. As public and private healthcare investments increase, along with rising awareness of early treatment, the demand for cephalosporins is expected to remain high across the Asia Pacific.

EUROPE CEPHALOSPORIN MARKET ANALYSIS

In Europe, the cephalosporin market is benefiting from an aging population and a rise in bacterial infections. Many elderly individuals are more prone to infections like UTIs, respiratory diseases, and pneumonia, all of which often require cephalosporin-based treatment. Cephalosporins are especially valued for their strong safety profile and coverage against multiple pathogens. Hospital-acquired infections are also increasing in Europe, prompting hospitals to stock advanced-generation antibiotics for better patient outcomes. Industry data indicates over 670,000 people in the EU contract antibiotic-resistant infections each year. This growing resistance makes newer cephalosporin options essential. Third-generation formulations are now widely used to manage severe cases of bloodstream infections, particularly those caused by resistant strains of E. coli. In 2023, roughly 10 out of every 100,000 people in the EU were affected by such resistant bloodstream infections, underlining the importance of updated treatments. Pharmaceutical companies across the region are focusing on creating new formulations and combination drugs to fight multi-drug-resistant bacteria. At the same time, health systems are under pressure to reduce costs, which is pushing demand for effective generics. These conditions are fueling steady growth in the European cephalosporin market.

LATIN AMERICA CEPHALOSPORIN MARKET ANALYSIS

The Latin America cephalosporin market is significantly influenced by the region's increasing investment in healthcare modernization and expansion, particularly in countries such as Brazil and Mexico. For instance, 9.47% of the GDP of Brazil is spent on healthcare, equating to USD 161 Billion and making Brazil the largest healthcare market in Latin America, as per the International Trade Administration (ITA). As healthcare access improves, there is a growing demand for both inpatient and outpatient antibiotic treatments, with cephalosporins being a preferred option for managing bacterial infections. Additionally, government programs aimed at controlling the spread of infections and improving public health are contributing substantially to industry expansion. The growing presence of multinational pharmaceutical companies and collaborations with local players are further boosting the availability of both branded and generic cephalosporins.

MIDDLE EAST AND AFRICA CEPHALOSPORIN MARKET ANALYSIS

The Middle East and Africa are experiencing a rising demand for cephalosporins due to persistent challenges from infectious diseases and improved access to healthcare. Rapid urban development and increasing public awareness about antibiotics have contributed to greater usage, particularly in countries such as Saudi Arabia, South Africa, and the United Arab Emirates. Government health budgets are expanding, supporting more structured infection control strategies. In Saudi Arabia, approximately 17% of the 2023 national budget roughly USD 50 Billion was allocated to healthcare, reflecting the growing state involvement in health delivery. As infrastructure improves and access to clinics and hospitals increases, more patients are receiving timely treatment. Cephalosporins are widely used as frontline antibiotics because they are both effective and familiar to practitioners. Policymakers are also introducing regulations to enhance antibiotic stewardship, thereby reducing misuse and guiding healthcare providers toward recommended medications. These combined factors are raising the demand for both branded and generic cephalosporins. As the region continues to strengthen healthcare systems and public health awareness grows, the market for cephalosporin-based treatments is expected to expand steadily.

COMPETITIVE LANDSCAPE:

Leading companies in the cephalosporin market are focusing on R&D to develop advanced formulations with better efficacy and fewer side effects, reflecting the shift toward safer and more effective treatments. To support a strong cephalosporin market forecast, firms are also expanding through acquisitions, partnerships, and global collaborations to access new markets and technologies. Regulatory compliance and sustainable manufacturing remain key priorities, underscoring their commitment to quality, safety, and environmental responsibility.

The report provides a comprehensive analysis of the competitive landscape in the cephalosporin market with detailed profiles of all major companies, including:

• Allergan Plc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Lupin Limited
• Merck & Co. Inc.
• Novartis International AG (Sandoz)
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Sun Pharmaceutical Industries Limited

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cephalosporin Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Generation
• 5.5 Market Breakup by Route of Administration
• 5.6 Market Breakup by Application
• 5.7 Market Breakup by Region
• 5.8 Market Forecast

6 Market Breakup by Generation

• 6.1 First Generation
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Second Generation
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Third Generation
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Fourth Generation
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Fifth Generation
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Injection
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Oral
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Respiratory Tract
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Skin Infection
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Ear Infection
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Urinary Tract Infection
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Sexually Transmitted Infection
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Others
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by Region

• 9.1 Asia Pacific
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Europe
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 North America
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Middle East and Africa
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Latin America
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

• 13.1 Price Indicators
• 13.2 Price Structure
• 13.3 Margin Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Allergan Plc.
  • 14.3.2 Bristol-Myers Squibb Company
  • 14.3.3 F. Hoffmann-La Roche Ltd.
  • 14.3.4 GlaxoSmithKline plc
  • 14.3.5 Lupin Limited
  • 14.3.6 Merck & Co. Inc.
  • 14.3.7 Novartis International AG (Sandoz)
  • 14.3.8 Pfizer Inc.
  • 14.3.9 Sanofi
  • 14.3.10 Teva Pharmaceutical Industries Ltd.
  • 14.3.11 Abbott
  • 14.3.12 Sun Pharmaceutical Industries Limited

List of Figures

• Figure 1: Global: Cephalosporin Market: Major Drivers and Challenges
• Figure 2: Global: Cephalosporin Market: Sales Value (in Billion USD), 2020-2025
• Figure 3: Global: Cephalosporin Market: Breakup by Generation (in %), 2025
• Figure 4: Global: Cephalosporin Market: Breakup by Route of Administration (in %), 2025
• Figure 5: Global: Cephalosporin Market: Breakup by Application (in %), 2025
• Figure 6: Global: Cephalosporin Market: Breakup by Region (in %), 2025
• Figure 7: Global: Cephalosporin Market Forecast: Sales Value (in Billion USD), 2026-2034
• Figure 8: Global: Cephalosporin (First Generation) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 9: Global: Cephalosporin (First Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 10: Global: Cephalosporin (Second Generation) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 11: Global: Cephalosporin (Second Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 12: Global: Cephalosporin (Third Generation) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 13: Global: Cephalosporin (Third Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 14: Global: Cephalosporin (Fourth Generation) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 15: Global: Cephalosporin (Fourth Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 16: Global: Cephalosporin (Fifth Generation) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 17: Global: Cephalosporin (Fifth Generation) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 18: Global: Cephalosporin (Injection) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 19: Global: Cephalosporin (Injection) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 20: Global: Cephalosporin (Oral) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 21: Global: Cephalosporin (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 22: Global: Cephalosporin (Respiratory Tract) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 23: Global: Cephalosporin (Respiratory Tract) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 24: Global: Cephalosporin (Skin Infection) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 25: Global: Cephalosporin (Skin Infection) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 26: Global: Cephalosporin (Ear Infection) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 27: Global: Cephalosporin (Ear Infection) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 28: Global: Cephalosporin (Urinary Tract Infection) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 29: Global: Cephalosporin (Urinary Tract Infection) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 30: Global: Cephalosporin (Sexually Transmitted Infection) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 31: Global: Cephalosporin (Sexually Transmitted Infection) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 32: Global: Cephalosporin (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
• Figure 33: Global: Cephalosporin (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 34: Asia Pacific: Cephalosporin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 35: Asia Pacific: Cephalosporin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 36: Europe: Cephalosporin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 37: Europe: Cephalosporin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 38: North America: Cephalosporin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 39: North America: Cephalosporin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 40: Middle East and Africa: Cephalosporin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 41: Middle East and Africa: Cephalosporin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 42: Latin America: Cephalosporin Market: Sales Value (in Million USD), 2020 & 2025
• Figure 43: Latin America: Cephalosporin Market Forecast: Sales Value (in Million USD), 2026-2034
• Figure 44: Global: Cephalosporin Industry: SWOT Analysis
• Figure 45: Global: Cephalosporin Industry: Value Chain Analysis
• Figure 46: Global: Cephalosporin Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Cephalosporin Market: Key Industry Highlights, 2025 and 2034
• Table 2: Global: Cephalosporin Market Forecast: Breakup by Generation (in Million USD), 2026-2034
• Table 3: Global: Cephalosporin Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
• Table 4: Global: Cephalosporin Market Forecast: Breakup by Application (in Million USD), 2026-2034
• Table 5: Global: Cephalosporin Market Forecast: Breakup by Region (in Million USD), 2026-2034
• Table 6: Global: Cephalosporin Market Structure
• Table 7: Global: Cephalosporin Market: Key Players